Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cork

Showing results (151-160 of 224) with videos related to

Pageof 23
Sort By:
Biomedical Optics Express|October 6, 2023
Potential application of PS-OCT in the safety assessment of non-steroidal topical creams for atopic dermatitis treatmentM Q Duan, Robert A Byers, Simon G Danby, et al.
Paediatric Drugs|December 18, 2022
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic DermatitisAmy S Paller, Elaine C Siegfried, Michael J Cork, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 31, 2008
Allelic variants of streptokinase from Streptococcus pyogenes display functional differences in plasminogen activationJason D McArthur, Fiona C McKay, Vidiya Ramachandran, et al.
The Journal of Allergy and Clinical Immunology|October 6, 2014
Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis preventionEric L Simpson, Joanne R Chalmers, Jon M Hanifin, et al.
Mbio|March 12, 2020
Vaccine-Induced Th1-Type Response Protects against Invasive Group A <i>Streptococcus</i> Infection in the Absence of Opsonizing AntibodiesTania Rivera-Hernandez, Mira Syahira Rhyme, Amanda J Cork, et al.
Dermatology and Therapy|September 26, 2023
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic DermatitisMichael J Cork, Diamant Thaçi, Lawrence F Eichenfield, et al.
Scientific Reports|February 24, 2021
A multivalent T-antigen-based vaccine for Group A StreptococcusJacelyn M S Loh, Tania Rivera-Hernandez, Reuben McGregor, et al.
Pediatric Dermatology|January 27, 2022
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial dataAmy S Paller, Lisa A Beck, Andrew Blauvelt, et al.
The Journal of Investigative Dermatology|March 2, 2005
Single-point haplotype scores telomeric to human leukocyte antigen-C give a high susceptibility major histocompatibility complex haplotype for psoriasis in a Caucasian populationNick Lench, Mark M Iles, Ian Mackay, et al.
Pediatric Dermatology|November 12, 2024
Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension StudyAmy S Paller, Michele Ramien, Michael J Cork, et al.
Pageof 23

Showing results (151-160 of 224) with videos related to

Sort By:
Pageof 23
Biomedical Optics Express|October 6, 2023
Potential application of PS-OCT in the safety assessment of non-steroidal topical creams for atopic dermatitis treatmentM Q Duan, Robert A Byers, Simon G Danby, et al.
Paediatric Drugs|December 18, 2022
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic DermatitisAmy S Paller, Elaine C Siegfried, Michael J Cork, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 31, 2008
Allelic variants of streptokinase from Streptococcus pyogenes display functional differences in plasminogen activationJason D McArthur, Fiona C McKay, Vidiya Ramachandran, et al.
The Journal of Allergy and Clinical Immunology|October 6, 2014
Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis preventionEric L Simpson, Joanne R Chalmers, Jon M Hanifin, et al.
Mbio|March 12, 2020
Vaccine-Induced Th1-Type Response Protects against Invasive Group A <i>Streptococcus</i> Infection in the Absence of Opsonizing AntibodiesTania Rivera-Hernandez, Mira Syahira Rhyme, Amanda J Cork, et al.
Dermatology and Therapy|September 26, 2023
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic DermatitisMichael J Cork, Diamant Thaçi, Lawrence F Eichenfield, et al.
Scientific Reports|February 24, 2021
A multivalent T-antigen-based vaccine for Group A StreptococcusJacelyn M S Loh, Tania Rivera-Hernandez, Reuben McGregor, et al.
Pediatric Dermatology|January 27, 2022
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial dataAmy S Paller, Lisa A Beck, Andrew Blauvelt, et al.
The Journal of Investigative Dermatology|March 2, 2005
Single-point haplotype scores telomeric to human leukocyte antigen-C give a high susceptibility major histocompatibility complex haplotype for psoriasis in a Caucasian populationNick Lench, Mark M Iles, Ian Mackay, et al.
Pediatric Dermatology|November 12, 2024
Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension StudyAmy S Paller, Michele Ramien, Michael J Cork, et al.
Pageof 23